Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand FDA Compliance for Peptide Therapy and BPC 157 Holt Law BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA's Overreach on Compounded Peptides